[Skip to Content]
[Skip to Content Landing]
March 2000

Improving the Outcome of Patients With Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome

Author Affiliations

Copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2000

Arch Dermatol. 2000;136(3):410-411. doi:10.1001/archderm.136.3.410

TOXIC EPIDERMAL necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are perhaps the most dramatic and severe adverse cutaneous reactions to drugs.1 Both of these related mucocutaneous disorders have associated high rates of morbidity and mortality.2 In this issue of the ARCHIVES, the group from Hôpital Henri Mondor in Créteil, France, presents the results of a retrospective study of the effect of the early withdrawal of causative drugs on the survival of patients with TEN and SJS.3 Because of the seriousness of these conditions and the lack of definitively effective treatment, there is a large body of literature advocating a variety of treatments, some of which are clearly beneficial, some of which are more likely to be harmful than helpful, and some of which are of great interest but still of unproven benefit.